Taressa Stanton
Payments from drug & device makers
Across 284 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$784
- Novo Nordisk$677
- AstraZeneca$647
- Amgen$472
- AbbVie$377
- Novartis$275
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,73798%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 52 | $784 |
| Novo Nordisk | 46 | $677 |
| AstraZeneca | 32 | $647 |
| Amgen | 28 | $472 |
| AbbVie | 28 | $377 |
| Novartis | 16 | $275 |
| Pfizer | 12 | $254 |
| Boehringer Ingelheim | 10 | $201 |
| Astellas Pharma US Inc | 4 | $152 |
| Phathom Pharmaceuticals, Inc. | 11 | $131 |
| GSK | 6 | $121 |
| Bayer | 5 | $98 |
| Exact Sciences | 5 | $90 |
| Sumitomo Pharma America, Inc. | 3 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| Amarin Pharma, Inc. | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Lexicon Pharmaceuticals, Inc. | 2 | $49 |
| Mylan Specialty L.p. | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Gilead | 2 | $35 |
| Viatris Specialty LLC | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Edwards Lifesciences | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Vertos Medical, Inc. | 1 | $12 |
How this compares
$4,837 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 280 | $401,902 |
| JardianceEmpagliflozin | 181 | $204,855 |
| FarxigaDapagliflozin Propanediol | 229 | $201,570 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $106,526 |
| OzempicSemaglutide | 80 | $105,582 |
| TrulicityDulaglutide | 78 | $96,772 |
| EliquisApixaban | 118 | $94,510 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 89 | $77,391 |
| Repatha SureclickEvolocumab | 82 | $71,593 |
| Xigduo XrDapaglifloz Propaned/Metformin | 69 | $70,352 |
| RybelsusSemaglutide | 23 | $38,068 |
| XareltoRivaroxaban | 41 | $30,859 |
| SynjardyEmpagliflozin/Metformin Hcl | 23 | $26,376 |
| VascepaIcosapent Ethyl | 42 | $22,362 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $19,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $784 | $498,673358 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $201 | $325,129310 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $647 | $221,099262 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $677 | $147,063115 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $121 | $120,042162 claims |
| PfizerEliquis | $254 | $94,510118 claims |
| AbbVieLinzess | $377 | $14,32111 claims |
| Astellas Pharma US IncMyrbetriq | $152 | $12,79413 claims |
| NovartisEntresto | $275 | $9,61411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.
Other family in Troy
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.